213 related articles for article (PubMed ID: 34455227)
41. Talazoparib to treat BRCA-positive breast cancer.
Guney Eskiler G
Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
[TBL] [Abstract][Full Text] [Related]
42. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
43. A review on mechanisms of resistance to PARP inhibitors.
Desai C; Pathak A; Limaye S; Maniar V; Joshi A
Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis.
Qureshi Z; Jamil A; Altaf F; Siddique R; Safi A
Am J Clin Oncol; 2024 Jun; ():. PubMed ID: 38899756
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with
Ma J; Deng H; Li J; Hu S; Yang Y; Liu S; Han X
Cancer Manag Res; 2019; 11():3061-3078. PubMed ID: 31114351
[No Abstract] [Full Text] [Related]
46. [PARP inhibitors in breast cancer: Current clinical development and perspectives].
Robbe J; Moretta J; Vicier C; Sabatier R; Noguès C; Gonçalves A
Bull Cancer; 2020 Oct; 107(10):1024-1041. PubMed ID: 33004179
[TBL] [Abstract][Full Text] [Related]
47. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
48. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
49. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
50. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
51. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A
BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233
[TBL] [Abstract][Full Text] [Related]
52. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
Chang XF; Ren XL; Yang JQ; Shi JJ; Bai JH; Cui MS; Dong WW
Breast; 2021 Oct; 59():44-50. PubMed ID: 34130011
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
Jiang Y; Zhao J; Zhang L; Tian S; Yang T; Wang L; Zhao M; Yang Q; Wang Y; Yang X
Front Oncol; 2020; 10():954. PubMed ID: 32719741
[No Abstract] [Full Text] [Related]
55. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
56. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
Kaneko M
Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
[TBL] [Abstract][Full Text] [Related]
57. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
58. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
Hashimoto K; Tamura K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
[TBL] [Abstract][Full Text] [Related]
59. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
60. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
